Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30% [Yahoo! Finance]
Candel Therapeutics, Inc. (CADL)
Company Research
Source: Yahoo! Finance
The considerable ownership by individual investors in Candel Therapeutics indicates that they collectively have a greater say in management and business strategy A total of 24 investors have a majority stake in the company with 50% ownership To get a sense of who is truly in control of Candel Therapeutics, Inc. ( NASDAQ:CADL ), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 48% to be precise, is individual investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company. And individual insiders on the other hand have a 30% ownership in the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Let's delve deeper into each type of owner of Candel Therapeutics, beginning with the chart below. What Does The Institutional Ownership Tell Us About Candel Th
Show less
Read more
Impact Snapshot
Event Time:
CADL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CADL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CADL alerts
High impacting Candel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CADL
News
- Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Candel Therapeutics reports Q3 results [Seeking Alpha]Seeking Alpha
- Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire
CADL
Analyst Actions
- 11/18/24 - HC Wainwright
CADL
Sec Filings
- 11/21/24 - Form 4
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- CADL's page on the SEC website